Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-08-2010

Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?

Authors: Martin Zweifel, Anwar R. Padhani

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Special Issue 1/2010

Abstract

Introduction

Classically, the first step in the clinical development of drugs in oncology involves assessments of dose limiting toxicity (DLT) and maximum tolerated dose (MTD). New paradigms are needed for antiangiogenic drugs and vascular disrupting agents (VDAs) as they are active at doses well below the MTD and as single agents their use might not translate into anti-tumour efficacy. MRI is able to assess the antivascular effects of antivascular drugs via changes in functional kinetic parameters; however, the usefulness of MRI in decision making has been questioned by many.

Objectives

Our aim is to review the experience of using dynamic contrast-enhanced MRI (DCE-MRI) in early clinical development of vascular directed anticancer therapies over the last decade. Thirty-nine phase I and II studies including data on more than 700 patients have been published as abstracts and/or papers, documenting DCE-MRI changes after the administration of antiangiogenic drugs and VDAs.

Discussion

Perfusion MRI is helpful in assessing whether mechanistic goals are achieved, in assisting dose selection for phase II studies, in selecting subpopulations enriched for response and in predicting patient benefit. Imaging tools are increasingly available. Future challenges for imaging include correlation with clinical measures of efficacy and determining relationships with blood and serum biomarkers.

Collins JM. Functional imaging in phase I studies: decorations or decision making? J Clin Oncol 2003;21:2807–9.CrossRefPubMed

Rüegg C, Meuwly JY, Driscoll R, Werffeli P, Zaman K, Stupp R. The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials. Curr Mol Med 2003;3:673–91.CrossRefPubMed

Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987–9.CrossRefPubMed

Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009;27:2542–52.CrossRefPubMed

Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83–95.CrossRefPubMed

Oostendorp M, Post MJ, Backes WH. Vessel growth and function: depiction with contrast-enhanced MR imaging. Radiology 2009;251:317–35.CrossRefPubMed

Kety S. Measurement of local blood flow by the exchange of an inert, diffusible substance. Methods Med Res 1960;8:228–36.

Kety S. Blood-tissue exchange methods. Theory of blood-tissue exchange and its application to measurement of blood flow. Methods Med Res 1960;8:223–7.

Tofts P, Brix G, Buckley D, Evelhoch J, Henderson E, Knopp M, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223–32.CrossRefPubMed

10.

Wilkinson ID, Jellineck DA, Levy D, Giesel FL, Romanowski CA, Miller BA, et al. Dexamethasone and enhancing solitary cerebral mass lesions: alterations in perfusion and blood-tumor barrier kinetics shown by magnetic resonance imaging. Neurosurgery 2006;58:640–6. discussion 640-6.CrossRefPubMed

11.

O’Connor JP, Carano RA, Clamp AR, Ross J, Ho CC, Jackson A, et al. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res 2009;15:6674–82.CrossRefPubMed

12.

Lankester KJ, Maxwell RJ, Pedley RB, Dearling JL, Qureshi UA. E, et al. Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down. Int J Oncol 2007;30:453–60.PubMed

13.

Lankester KJ, Taylor JN, Stirling JJ, Boxall J, d’Arcy JA, Collins DJ, et al. Dynamic MRI for imaging tumor microvasculature: comparison of susceptibility and relaxivity techniques in pelvic tumors. J Magn Reson Imaging 2007;25:796–805.CrossRefPubMed

14.

Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005;92:1599–610.CrossRefPubMed

15.

Lankester KJ, Taylor NJ, Stirling JJ, Boxall J, D’Arcy JA, Leach MO, et al. Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI. Br J Cancer 2005;93:979–85.CrossRefPubMed

16.

Thukral A, Thomasson DM, Chow CK, Eulate R, Wedam SB, Gupta SN, et al. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab–initial experience. Radiology 2007;244:727–35.CrossRefPubMed

17.

Walker-Samuel S, Parker CC, Leach MO, Collins DJ. Reproducibility of reference tissue quantification of dynamic contrast-enhanced data: comparison with a fixed vascular input function. Phys Med Biol 2007;52:75–89.CrossRefPubMed

18.

Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760–4.CrossRefPubMed

19.

Taylor NJ, Tunariu N, Stirling JJ, Collins DJ, Nathan P, d’Arcy JA, et al. Non-enhancing pixels: a specific additional DCE-MRI kinetic parameter for assessing antivascular effects of anti-angiogenic and vascular disruptive agents. Proceedings of the joint meeting of International Society of Magnetic Resonance in Medicine, 16th Scientific Meeting and Exhibition, Honolulu; 2009. p. 2262.

20.

Weinmann HJ, Laniado M, Mützel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984;16:167–72.PubMed

21.

Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7:91–101.CrossRefPubMed

22.

Buckley DL. Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn Reson Med 2002;47:601–6.CrossRefPubMed

23.

Landis CS, Li X, Telang FW, Coderre JA, Micca PL, Rooney WD, et al. Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange. Magn Reson Med 2000;44:563–74.CrossRefPubMed

24.

Buckley DL. Transcytolemmal water exchange and its affect on the determination of contrast agent concentration in vivo. Magn Reson Med 2002;47:420–4.CrossRefPubMed

25.

Schlemmer HP, Merkle J, Grobholz R, Jaeger T, Michel MS, Werner A, et al. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 2004;14:309–17.CrossRefPubMed

26.

Padhani AR, Dzik-Jurasz A. Perfusion MR imaging of extracranial tumor angiogenesis. Top Magn Reson Imaging 2004;15:41–57.CrossRefPubMed

27.

Ferrier MC, Sarin H, Fung SH, Schatlo B, Pluta RM, Gupta SN, et al. Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia 2007;9:546–55.CrossRefPubMed

28.

Eby PR, Partridge SC, White SW, Doot RK, Dunnwald LK, Schubert EK, et al. Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer. Acad Radiol 2008;15:1246–54.CrossRefPubMed

29.

Niermann KJ, Fleischer AC, Huamani J, Yankeelov TE, Kim DW, Wilson WD, et al. Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. J Ultrasound Med 2007;26:749–56.PubMed

30.

Conrad C, Friedman H, Reardon D, Provenzale J, Jackson E, Serajuddin H, et al. A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol (Meeting Abstracts), 2004. Vol. 22.

31.

Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21:3955–64.CrossRefPubMed

32.

Mross K, Drevs J, Müller M, Medinger M, Marmé D, Hennig J, et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 2005;41:1291–9.CrossRefPubMed

33.

Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005;23:4162–71.CrossRefPubMed

34.

Drevs J, Medinger M, Mross K, Zirrgiebel U, Strecker R, Unger C, et al. Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 2005;23:3002.

35.

Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005;23:5464–73.CrossRefPubMed

36.

Medved M, Karczmar G, Yang C, Dignam J, Gajewski TF, Kindler H, et al. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: variability and changes in tumor tissue over time. J Magn Reson Imaging 2004;20:122–8.CrossRefPubMed

37.

O’Donnell A, Padhani A, Hayes C, Kakkar AJ, Leach M, Trigo JM, et al. A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer 2005;93:876–83.CrossRefPubMed

38.

Dowlati A, Robertson K, Radivoyevitch T, Waas J, Ziats NP, Hartman P, et al. Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin Cancer Res 2005;11:7938–44.CrossRefPubMed

39.

Xiong HQ, Herbst R, Faria SC, Scholz C, Davis D, Jackson EF, et al. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs 2004;22:459–66.CrossRefPubMed

40.

Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:2369–76.CrossRefPubMed

41.

Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002;94:1484–93.PubMed

42.

Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008;26:4572–8.CrossRefPubMed

43.

Flaherty KT, Rosen MA, Heitjan DF, Gallagher ML, Schwartz B, Schnall MD, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008;7:496–501.PubMed

44.

Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, et al. A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009;69:5296–300.CrossRefPubMed

45.

Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009;27:3027–35.CrossRefPubMed

46.

Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:769–77.CrossRefPubMed

47.

Overmoyer B, Silverman P, Leeming R, Shenk R, Lyons J, Ziats N, et al. Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings. 2004;22:Abstract 727.

48.

Baar J, Silverman P, Lyons J, Fu P, Abdul-Karim F, Ziats N, et al. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res 2009;15:3583–90.CrossRefPubMed

49.

Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002;20:3826–40.CrossRefPubMed

50.

McKeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, Ravic M, et al. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 2006;12:1776–84.CrossRefPubMed

51.

Evelhoch J, LoRusso P, DelProposto Z, Stark K, Latif Z, Morton P, et al. Dynamic contrast-enhanced MRI evaluation of the effects of ZD6126 on tumor vasculature in a phase I clinical trial, Proc. ISMRM, Honolulu, Hawaii, 2002. Vol. 10.

52.

LoRusso PM, Gadgeel SM, Wozniak A, Barge AJ, Jones HK, DelProposto ZS, et al. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 2008;26:159–67.CrossRefPubMed

53.

Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21:2815–22.CrossRefPubMed

54.

Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831–42.CrossRefPubMed

55.

Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408–16.PubMed

56.

Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428–38.CrossRefPubMed

57.

Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, et al. Phase I trial of combretastatin A-4 phosphate with carboplatin. Clin Cancer Res 2005;11:1527–33.CrossRefPubMed

58.

Nathan P, Judson I, Padhani A, Harris A, Carden CP, Smythe J, et al. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 2008;26:3550.CrossRef

59.

Akerley WL, Schabel M, Morrell G, Horvath E, Yu M, Johnsson B, et al. A randomized phase 2 trial of combretastatin A4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. 2007;25:14060.

60.

Meyer T, Gaya AM, Dancey G, Stratford MR, Othman S, Sharma SK, et al. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res 2009;15:4484–92.CrossRefPubMed

61.

Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006;313:1785–7.CrossRefPubMed

62.

Padhani AR, Koh DM, Taylor NJ, Stirling JJ, Collins DJ, Rustin GJ, et al. DCE-MRI demonstration of antivascular effects of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to human subjects with advanced solid tumours. Proceedings of the joint meeting of International Society of Magnetic Resonance in Medicine and European Society for Magnetic Resonance in Medicine and Biology 2008:Oral presentation. Program number 773.

63.

Anderson H, Yap JT, Wells P, Miller MP, Propper D, Price P, et al. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer 2003;89:262–7.CrossRefPubMed

64.

Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 2005;23:973–81.CrossRefPubMed

65.

Padhani AR, Taylor NJ, d’Arcy JA, Walker-Samuel S, Collins DJ, Knowles B, et al. Dynamic MRI evaluation of the triple receptor tyrosine kinase inhibitor BIBF 1120 in patients with advanced solid tumours. Proc Int Soc Magn Reson Med 2006;14:765.

66.

Strecker R, Mross K, Stefanic M, de Rossi L, Hennig J. Evaluation of the effects of the triple angiokinase inhibitor BIBF 1120 on tumor vasculature in a phase I clinical trial using dynamic contrast-enhanced MRI (DCE-MRI). Proc Int Soc Magn Reson Med 2006;14:764.

67.

Jonker DJ, Rosen LS, Sawyer M, Wilding G, Noberasco C, Jayson G, et al. A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. 2007;25:Abstract 3559.

68.

NCI. Recommendations for MR measurement methods at 1.5-Tesla and endpoints for use in Phase 1/2a trials of anti-cancer therapeutics affecting tumor vascular function. http://imaging.cancer.gov/images/Documents/14a39040-dad1-46f8-bf88-bae2e7401ebe/DCE_RecommendationfromNov2004NCIWorkshop(2).pdf, 2004.

69.

70.

Evelhoch J, Garwood M, Vigneron D, Knopp M, Sullivan D, Menkens A, et al. Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report. Cancer Res 2005;65:7041–4.CrossRefPubMed

71.

Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145–7.CrossRefPubMed

72.

Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002;20:3804–14.CrossRefPubMed

73.

Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009;15:167–70.CrossRefPubMed

74.

Patterson DM, Padhani AR, Collins DJ. Technology insight: water diffusion MRI—a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol 2008;5:220–33.CrossRefPubMed

75.

O’Dwyer PJ, Rosen M, Gallagher M, Schwartz B, Flaherty KT. Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma. J Clin Oncol (Meeting Abstracts). 2005;23:3005.

76.

Rosen LS, Wilding G, Sweeney C, Casale D, Kollia G, Wu C, et al. Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors. J Clin Oncol (Meeting Abstracts). 2006;24:3051.

77.

Mross KB, Gmehling D, Frost A, Baas F, Strecker R, Hennig J, et al. A clinical phase I, pharmacokinetic (PK), and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients. J Clin Oncol (Meeting Abstracts), 2005. Vol. 23.

78.

Eder Jr JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002;20:3772–84.CrossRefPubMed

79.

Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003;21:223–31.CrossRefPubMed

80.

Watson Y, Cheung S, Roberts C, Buonaccorsi G, Davies K, Jackson A, et al. Prognostic power of DCE-MRI heterogeneity analysis in patients with advanced solid tumors. Proc Int Soc Magn Reson Med 2006;14:755.

81.

Perotti A, Sessa C, Mancuso A, Noberasco C, Cresta S, Locatelli A, et al. Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. Ann Oncol 2009;20:741–5.CrossRefPubMed

82.

Patterson DM, Charnley N, Saleem A, Stratford M, Dickinson C, Asselin M, et al. Phase I evaluation of vascular disrupting agent OXi4503. J Clin Oncol. 2008;26:Abstract 3551.

83.

Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004;10:3650–7.CrossRefPubMed

Title: Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?
Authors: Martin Zweifel
Anwar R. Padhani
Publication date: 01-08-2010
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue Special Issue 1/2010
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1451-z

2024 ASCO Annual Meeting

Springer Medicine

Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?

Abstract

Introduction

Objectives

Discussion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Introduction

Objectives

Discussion

Please log in to get access to this content

Other articles of this Special Issue 1/2010

Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements

Inorganic nanomaterials for tumor angiogenesis imaging

Imaging of angiogenesis: from morphology to molecules and from bench to bedside

Contrast-enhanced ultrasound for molecular imaging of angiogenesis

Positron emission tomography tracers for imaging angiogenesis

Radionuclide imaging of perfusion and hypoxia